We excluded 1) those with diagnoses of AF, atrial tachycardia, ventricular tachycardia, ventricular fibrillation, mechanical valve, hyperthyroidism, or mitral stenosis before or on the index date, 2) those with cardiac events (i.e., myocardial infarction, percutaneous intervention, valve/bypass surgery) in the preceding 3 months, 3) those currently receiving antiarrhythmic medications (e.g., amiodarone, dronedarone, flecainide, propafenone, or dofetilide) on the index date, 4) those who used insulin within one year prior or on the index date, and 5) those who do not have hemoglobin A1C (HbA1c) within one year prior or on the index date (eFigure 1)
It is also worth checking in if your symptoms have not eased after the usual adjustment window of roughly four to eight weeks, since lingering issues can point to something that deserves a closer look
The active molecule and its GLP-1 receptor mechanism are the same, but formulation, oversight, and labeling differ
Amgen Fellow Big Pharma firm Amgen, with its own GLP-1 MariTide (maridebart cafraglutide, formerly AMG 133) in the clinic, reiterated the need to invest in its own manufacturing network during its third-quarter call this week
Planning ahead From an aesthetic perspective, the priority should be to plan rather than panic
